Quanterix - QTRX Stock Forecast, Price & News

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Quanterix in the last year. There are currently 6 hold ratings and 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "hold" QTRX shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in QTRX, but not buy additional shares or sell existing shares.
View QTRX analyst ratings or view top-rated stocks.

7 analysts have issued 1-year price targets for Quanterix's stock. Their QTRX share price forecasts range from $12.00 to $60.00. On average, they anticipate the company's stock price to reach $26.00 in the next twelve months. This suggests a possible upside of 95.5% from the stock's current price.
View analysts price targets for QTRX or view top-rated stocks among Wall Street analysts.

Quanterix's stock was trading at $42.40 at the beginning of the year. Since then, QTRX stock has decreased by 68.6% and is now trading at $13.30.
View the best growth stocks for 2022 here.

The company is scheduled to release its next quarterly earnings announcement on Tuesday, March 7th 2023.
View our QTRX earnings forecast.

Quanterix Co. (NASDAQ:QTRX) issued its earnings results on Tuesday, November, 8th. The company reported ($0.40) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.42) by $0.02. The company earned $26.65 million during the quarter, compared to the consensus estimate of $22.56 million. Quanterix had a negative trailing twelve-month return on equity of 18.91% and a negative net margin of 89.24%.

15 employees have rated Quanterix Chief Executive Officer Kevin Hrusovsky on Glassdoor.com. Kevin Hrusovsky has an approval rating of 70% among the company's employees.

Based on aggregate information from My MarketBeat watchlists, some companies that other Quanterix investors own include Editas Medicine (EDIT), Novavax (NVAX), Akoustis Technologies (AKTS), Advanced Micro Devices (AMD), CRISPR Therapeutics (CRSP), Walt Disney (DIS), Illumina (ILMN), Sorrento Therapeutics (SRNE), Cisco Systems (CSCO) and Intellia Therapeutics (NTLA).

(QTRX) raised $50 million in an IPO on Thursday, December 7th 2017. The company issued 3,300,000 shares at $14.00-$16.00 per share. J.P. Morga and Leerink Partners served as the underwriters for the IPO and BTIG and Evercore ISI were co-managers.

Quanterix trades on the NASDAQ under the ticker symbol "QTRX."

Quanterix's stock is owned by a variety of institutional and retail investors. Top institutional investors include BlackRock Inc. (7.23%), Frontier Capital Management Co. LLC (5.22%), Vanguard Group Inc. (4.91%), Platinum Investment Management Ltd. (3.12%), Ashford Capital Management Inc. (2.43%) and Portolan Capital Management LLC (2.05%). Insiders that own company stock include Amol Chaubal, David C Duffy, David C Duffy, David R Walt, Dawn Mattoon, E Kevin Hrusovsky, John J Fry, John J Fry, Marijn E Dekkers, Marijn E Dekkers, Mark T Roskey, Mark T Roskey, Martin D Madaus, Masoud Toloue and Michael A Doyle.
View institutional ownership trends.

Shares of QTRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of QTRX stock can currently be purchased for approximately $13.30.

Quanterix (NASDAQ:QTRX) has a market capitalization of $492.83 million and generates $110.56 million in revenue each year. The company earns $-57,690,000.00 in net income (profit) each year or ($2.66) on an earnings per share basis.

The company employs 460 workers across the globe.

Quanterix's mailing address is 900 MIDDLESEX TURNPIKE, BILLERICA MA, 01821. The official website for the company is www.quanterix.com. The company can be reached via phone at (617) 301-9400 or via email at ir@quanterix.com.